Table 1.
Participant Characteristics.
| Characteristics | All Participants (n = 62) | Participants Initially Allocated to | ||
|---|---|---|---|---|
| Placebo (n = 31) | Resveratrol (n = 31) | p Value | ||
| Age (years) | 37.5 ± 0.8 | 37.4 ± 1.1 | 37.6 ± 1.1 | 0.887 |
| Years with hormonal migraine † | 11.4 ± 1.0 | 11.5 ± 1 | 11.3 ± 14 | 0.915 |
| Menstrual cycle length † | 28.4 ± 0.2 | 28.4 + 0.4 | 28.3 + 0.3 | 0.877 |
| Headache impact test-6™ | 63.5 ± 0.7 | 63.9 ± 1.2 | 63.1 ± 0.9 | 0.395 |
| Migraine disability assessment | ||||
| Total score | 19.6 ± 1.8 | 18 ± 1.9 | 21.1 ± 3.2 | 0.433 |
| Item A | 11.8 ± 0.9 | 11.2 ± 1.2 | 12.4 ± 1.4 | 0.575 |
| Item B | 6.6 ± 0.2 | 6.5 ± 0.3 | 6.7 ± 0.3 | 0.511 |
| Migraine-specific quality of life | ||||
| Emotional function domain | 48.8 ± 3.5 | 48.4 ± 5.4 | 49.2 ± 4.6 | 0.914 |
| Role function preventive domain | 60.3 ± 3.1 | 61.9 ± 4.2 | 58.7 ± 4.7 | 0.626 |
| Role function restrictive domain | 44.1 ± 3.0 | 46.3 ± 4.5 | 41.9 ± 4.0 | 0.496 |
| Estimated HMBI (migraine days/month) | 3.1 ± 0.2 | 3.0 ± 0.2 | 3.1 ± 0.3 | 0.862 |
| Contraception use (yes) | 16 (26%) | 8 (26%) | 8 (26%) | 1.000 |
| Smoking history (yes) | 10 (16%) | 4 (13%) | 6 (19%) | 0.490 |
| Guessed allocation correctly (%) ‡ | 35 (56%) | 15 (48%) | 20 (65%) | 0.205 |
† Based on recall. ‡ Independent t-test. The Headache impact test-6™ score ranges between 36–78; a higher the score represents a greater impact of migraine on an individual’s ability to function at work, home and social settings. The total Migraine disability assessment score ranges between 0–270; a higher the score represents a greater migraine-related disability. Migraine disability assessment item A and item B represent the average migraine frequency and the average pain intensity during the previous three-month period, respectively. A higher Migraine-specific quality of life domain score represents a better quality of life (self-perceived).